AbbVie stock slips despite Q3 2026 beat (ABBV:NYSE)
· seekingalpha.com
AbbVie (ABBV) stock slips even as the company posted better than expected Q3 2026 financials and lifted its full-ytear outlook. Read more here.
AbbVie (ABBV) topped expectations with its Q3 2026 financials on Friday as its newer immunology drugs, Skyrizi and Rinvoq, offset an anticipated sales contracti...